Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности телмисартана в АНГИО- и КАрдиопротекции и улучшении показателей углеводного обмена при нарушении толерантности к глюкозе
Возможности телмисартана в АНГИО- и КАрдиопротекции и улучшении показателей углеводного обмена при нарушении толерантности к глюкозе
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ключевые слова: артериальная гипертензия, метаболический синдром, телмисартан
________________________________________________
Полный текст
Список литературы
1. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541–5.
2. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21.
3. Nishimura H, Sanaka T, Tanihata Y et al. Losartan Elevates the Serum High-Molecular Weight-Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 2008; 31: 1611–8.
4. Sasaki T, Noda Y, Yasuoka Y et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 2008; 3: 921–9.
5. Derosa G, Cicero A, D'angelo D et al. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α. Hypertens Res 2006; 29: 849–56.
6. Benson SC, Pershadsingh HA, ITO CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 1–10.
7. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15 (4): 6.
2. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21.
3. Nishimura H, Sanaka T, Tanihata Y et al. Losartan Elevates the Serum High-Molecular Weight-Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 2008; 31: 1611–8.
4. Sasaki T, Noda Y, Yasuoka Y et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 2008; 3: 921–9.
5. Derosa G, Cicero A, D'angelo D et al. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α. Hypertens Res 2006; 29: 849–56.
6. Benson SC, Pershadsingh HA, ITO CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 1–10.
7. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15 (4): 6.
2. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21.
3. Nishimura H, Sanaka T, Tanihata Y et al. Losartan Elevates the Serum High-Molecular Weight-Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 2008; 31: 1611–8.
4. Sasaki T, Noda Y, Yasuoka Y et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 2008; 3: 921–9.
5. Derosa G, Cicero A, D'angelo D et al. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α. Hypertens Res 2006; 29: 849–56.
6. Benson SC, Pershadsingh HA, ITO CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 1–10.
7. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15 (4): 6.
________________________________________________
2. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21.
3. Nishimura H, Sanaka T, Tanihata Y et al. Losartan Elevates the Serum High-Molecular Weight-Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 2008; 31: 1611–8.
4. Sasaki T, Noda Y, Yasuoka Y et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 2008; 3: 921–9.
5. Derosa G, Cicero A, D'angelo D et al. Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α. Hypertens Res 2006; 29: 849–56.
6. Benson SC, Pershadsingh HA, ITO CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 1–10.
7. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 15 (4): 6.
Авторы
С.В.Недогода, И.Н.Барыкина, У.А.Брель, Т.А.Чаляби, Г.В.Мазина, Е.В.Подольская, А.А.Ледяева
Волгоградский государственный медицинский университет
The Volgograd state medical university
Волгоградский государственный медицинский университет
________________________________________________
The Volgograd state medical university
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.